The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1O52UA     propan-2-yl(2S)-2-[[2- [(2R,3S)-2-[[(2R)-2...

Synonyms: L-744832, L 744832, L 744,832, 160141-09-3
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of L-744832


High impact information on L-744832

  • L-744,832 inhibited H-Ras prenylation in cell lines and in primary hematopoietic cells and abrogated the in vitro growth of myeloid progenitor colonies in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) [3].
  • To determine whether functional p53 is required for L-744,832-induced apoptosis and the resultant tumor regression, MMTV-v-Ha-ras mice were interbred with p53(-/-) mice [2].
  • The ras/myc tumors were found to respond nearly as efficiently to L-744,832 treatment as the MMTV-v-Ha-ras tumors, although no induction of apoptosis was observed [2].
  • Tumors in ras/p53(-/-) mice treated with L-744,832 regressed as efficiently as MMTV-v-Ha-ras tumors, although this response was found to be mediated by both the induction of apoptosis and an increase in G1 with a corresponding decrease in the S-phase fraction [2].
  • We analyzed the level of processing of N-Ras and H-Ras after immunoprecipitation and Western blotting of protein extracts obtained from mammary tumors treated with L-744,832 or vehicle, either in vivo or in vitro (after primary culture of the same tumors), and from several in vitro treated control cell lines [5].

Chemical compound and disease context of L-744832


Biological context of L-744832


Anatomical context of L-744832

  • We have tested the effect of the FPTase inhibitor L-744,832 (FTI) on the anchorage-dependent and -independent growth of human tumor cell lines [9].
  • Significant growth inhibition (>70%) in myeloid cell lines was observed for GGTI-286 (9/19), GGTI-298 (14/19), GGTI-2147 (16/19) and FTI L-744,832 (17/17) [10].

Gene context of L-744832

  • L-744,832 potently inhibits the secretion of VEGF under hypoxic conditions [11].
  • Additionally, the data suggest that although the FTI L-744,832 can inhibit tumor growth in this model, Ki-Ras may not be the sole mediator of the biological effects of the FTI [4].
  • In this study, we hypothesized that the use of farnesyltransferase inhibitor (FTI, L-744,832) may directly restore TGF-beta signaling through RII expression via ras dependent or independent pathway leading to induction of radiation sensitivity [12].
  • L-744,832 is capable of inducing apoptosis in astrocytoma cells under anchorage-dependent conditions; this process occurs in a p53-independent manner and is associated with increased expression of Bax and Bak [11].
  • In addition, such effect of PKC is Ras-dependent as specific Ras inhibitor L-744,832 attenuated both PMA mediated induction of Erk 1/2 phosphorylation as well as HGF secretion [13].

Analytical, diagnostic and therapeutic context of L-744832

  • For mechanistic analyses, tumor excision biopsies were obtained from 12 mice before and after treatment with L-744,832 [14].
  • CONCLUSIONS: L-744,832 could be safely administered over a protracted period of time to mice at doses which were markedly inhibitory to the growth of three human prostate tumor xenografts and in combination with PTXL was also well tolerated and brought about some regression of the TSU-PR1 tumor [15].


  1. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Kohl, N.E., Omer, C.A., Conner, M.W., Anthony, N.J., Davide, J.P., deSolms, S.J., Giuliani, E.A., Gomez, R.P., Graham, S.L., Hamilton, K. Nat. Med. (1995) [Pubmed]
  2. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Barrington, R.E., Subler, M.A., Rands, E., Omer, C.A., Miller, P.J., Hundley, J.E., Koester, S.K., Troyer, D.A., Bearss, D.J., Conner, M.W., Gibbs, J.B., Hamilton, K., Koblan, K.S., Mosser, S.D., O'Neill, T.J., Schaber, M.D., Senderak, E.T., Windle, J.J., Oliff, A., Kohl, N.E. Mol. Cell. Biol. (1998) [Pubmed]
  3. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Mahgoub, N., Taylor, B.R., Gratiot, M., Kohl, N.E., Gibbs, J.B., Jacks, T., Shannon, K.M. Blood (1999) [Pubmed]
  4. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Omer, C.A., Chen, Z., Diehl, R.E., Conner, M.W., Chen, H.Y., Trumbauer, M.E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M.T., Davide, J.P., Ellis, M.S., Gibbs, J.B., Greenberg, I., Koblan, K.S., Kral, A.M., Liu, D., Lobell, R.B., Miller, P.J., Mosser, S.D., O'Neill, T.J., Rands, E., Schaber, M.D., Senderak, E.T., Oliff, A., Kohl, N.E. Cancer Res. (2000) [Pubmed]
  5. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Mangues, R., Corral, T., Kohl, N.E., Symmans, W.F., Lu, S., Malumbres, M., Gibbs, J.B., Oliff, A., Pellicer, A. Cancer Res. (1998) [Pubmed]
  6. Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU. Kavgaci, H., Ozdemir, F., Ovali, E., Yavuz, A., Yavuz, M., Aydin, F. Chemotherapy. (2005) [Pubmed]
  7. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. Law, B.K., Norgaard, P., Moses, H.L. J. Biol. Chem. (2000) [Pubmed]
  8. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Birkenkamp, K.U., Geugien, M., Schepers, H., Westra, J., Lemmink, H.H., Vellenga, E. Leukemia (2004) [Pubmed]
  9. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N.E., Gibbs, J.B., Oliff, A., Rosen, N. Cancer Res. (1995) [Pubmed]
  10. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Morgan, M.A., Wegner, J., Aydilek, E., Ganser, A., Reuter, C.W. Leukemia (2003) [Pubmed]
  11. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Feldkamp, M.M., Lau, N., Guha, A. Oncogene (1999) [Pubmed]
  12. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Alcock, R.A., Dey, S., Chendil, D., Inayat, M.S., Mohiuddin, M., Hartman, G., Chatfield, L.K., Gallicchio, V.S., Ahmed, M.M. Oncogene (2002) [Pubmed]
  13. PKC, p42/44 MAPK and p38 MAPK regulate hepatocyte growth factor secretion from human astrocytoma cells. Chattopadhyay, N., Tfelt-Hansen, J., Brown, E.M. Brain Res. Mol. Brain Res. (2002) [Pubmed]
  14. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Nørgaard, P., Law, B., Joseph, H., Page, D.L., Shyr, Y., Mays, D., Pietenpol, J.A., Kohl, N.E., Oliff, A., Coffey, R.J., Poulsen, H.S., Moses, H.L. Clin. Cancer Res. (1999) [Pubmed]
  15. A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Sirotnak, F.M., Sepp-Lorenzino, L., Kohl, N.E., Rosen, N., Scher, H.I. Cancer Chemother. Pharmacol. (2000) [Pubmed]
WikiGenes - Universities